^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Bladder Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    linrodostat (BMS-986205) (IDO1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).

    Published date:
    05/16/2018
    Excerpt:
    ORR in pts with tumor PD-L1 ≥ 1% (Dako PD-L1 IHC 28-8 pharmDx assay; n = 15) vs < 1% (n = 11) was 47% vs 27%.
    DOI:
    10.1200/JCO.2018.36.15_suppl.4512
    Trial ID:
    NCT02658890